Discovery could redirect drug development for disease affecting 6.7 million Americans The two AMPKα isoforms can have ...

The intricate link between endocrine disorders and cancer development has drawn significant interest, revealing how ...

Independent analysis examines why 'natural Ozempic alternative' and 'berberine weight loss patch' searches are driving ...

Examination of transdermal berberine delivery, GLP-1 pathway terminology in supplement marketing, and consumer evaluation ...

An international research team reveals new molecular mechanisms associated with pathogenic mutations in the protein ...

Learn how magnesium and berberine may support blood sugar control, how to take them safely, and what to know before combining ...

Atacicept, a novel dual inhibitor of BAFF and APRIL, receives FDA Priority Review for IgA nephropathy treatment in adults.

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases. Nimbus, an ...